Treatment of Refractory Linear IgA Bullous Dermatosis: Third-Line Options
This protocol applies to patients with Linear IgA bullous dermatosis whose disease has not responded adequately to earlier management and who require third-line systemic therapy for refractory disease.
Therapeutic approach
Third-line management of refractory Linear IgA bullous dermatosis draws on a range of systemic agents spanning immunomodulatory and biologic options. Agent selection is guided by individual patient factors and prior treatment history.
The complete protocol — including specific agents, their selection criteria, and administration guidance — is available via the link below.
References
DOI: 10.1111/jdv.19880
The recommended dose is 2g/kg given over 3-5days in monthly intervals.
View source ↗